1192. Deputy Pádraig O'Sullivan asked the Minister for Health given that European data indicates significant variability between member states in the reimbursement of orphan medicines for rare diseases, the steps her Department is taking to align Ireland's rare disease reimbursement framework with comparable EU jurisdictions; and if she will make a statement on the matter. [33127/26]
Topics / Medicinal Products
A subject heading for parliamentary questionsMedicinal Products
1,233 questions from 132 TDs, between 22 January 2025 and 22 October 2026.
1,233
questions
1,229 written, 4 oral
132
TDs have asked
11
parties and groups
Independents counted together
4
departments asked
Questions per month
The record holds no questions for August, when the Dáil does not sit.
Jan 2025Oct 2026
Show as a table
| Month | Questions |
|---|---|
| January 2025 | 17 |
| February 2025 | 66 |
| March 2025 | 28 |
| April 2025 | 35 |
| May 2025 | 43 |
| June 2025 | 58 |
| July 2025 | 56 |
| August 2025 | 0 |
| September 2025 | 36 |
| October 2025 | 38 |
| November 2025 | 58 |
| December 2025 | 27 |
| January 2026 | 18 |
| February 2026 | 70 |
| March 2026 | 142 |
| April 2026 | 87 |
| May 2026 | 156 |
| June 2026 | 127 |
| July 2026 | 82 |
| August 2026 | 0 |
| September 2026 | 62 |
| October 2026 | 27 |
Who asks, by party
The party each TD belonged to on the day, in alphabetical order. Parties differ a lot in size, and members of the Government answer questions rather than ask them, so this shows who raised it, not how much a party cares about it.
The TDs who asked most
Members of the Government answer questions rather than ask them. Each question counts once.
-
196
-
75
-
43
-
42
-
39
-
26
-
26
-
26
Asked of
Debated under the same heading
Debates whose official heading is exactly these words.
The questions
1193. Deputy Pádraig O'Sullivan asked the Minister for Health in light of the Health Products Regulatory Authority confirming that over 750,000 dosage units of falsified and illegal medicines were detained in 2025, with a thirty-fold increase in unauthorised GLP-1 type products, whether her Department has assessed the extent to which restricted access to authorised, reimbursed GLP-1 treatments through the HSE is driv…
1194. Deputy Pádraig O'Sullivan asked the Minister for Health the public awareness measures her Department and the HPRA are undertaking to alert the public to the serious health risks associated with sourcing prescription medicines through unauthorised online channels, particularly in respect of GLP-1 medicines marketed as drops or microneedle patches; and if she will make a statement on the matter. [33129/26]
1249. Deputy Mark Wall asked the Minister for Health to clarify whether AEDs are covered under the drugs payment scheme; and if she will make a statement on the matter. [33443/26]
441. Deputy Michael Fitzmaurice asked the Minister for Health when brensocatib, although approved will be made available in Ireland; and if she will make a statement on the matter. [31571/26]
445. Deputy Michael Cahill asked the Minister for Health the percentage of the HSE medicines budget that is currently spent on 'non-oncology medicines for rare diseases; and if she will make a statement on the matter. [31631/26]
453. Deputy Marie Sherlock asked the Minister for Health if she has requested the NCPP to consider a full review of relugolix with estradiol and norethisterone acetate. [31687/26]
454. Deputy Marie Sherlock asked the Minister for Health the submitted price of ryeqo (relugolix with estradiol and norethisterone acetate) at the time of the rapid review by the NCPP in 2022. [31688/26]
455. Deputy Marie Sherlock asked the Minister for Health to list the grounds upon which the NCPP rejected a full HTA examination of Ryeqo. [31689/26]
272. Deputy Jennifer Whitmore asked the Minister for Health if she will consider approving access to xolair for a person (details supplied); and if she will make a statement on the matter. [31098/26]
274. Deputy Thomas Gould asked the Minister for Health whether she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for Frederich's ataxia which currently can be classed as having an 'unmet need' as outlined in the National Rare Disease Strategy 2025 - 2030. [31101/26]
275. Deputy Thomas Gould asked the Minister for Health her views on whether the current delay in the reimbursement of skyclarys aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [31102/26]
999. Deputy Paul Donnelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the skyclarys reimbursement negotiations (details supplied); and her views on whether the current delay aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [29564/26]
1000. Deputy Louis O'Hara asked the Minister for Health the measures being taken to improve the timeliness of access to orphan drugs in Ireland, particularly in cases such as Friedreich's ataxia, where a treatment has been approved by the EMA but is not yet reimbursed by the HSE; and if she will make a statement on the matter. [29565/26]
1184. Deputy Martin Daly asked the Minister for Health if she will intervene to ensure that the Health Service Executive urgently prioritises the conclusion of reimbursement negotiations for skyclarys for the treatment of Friedreich’s ataxia, given that it is currently the only available treatment for this progressive and life-limiting rare disease and that Friedreich’s ataxia may be considered as having an “unmet ne…
1185. Deputy Martin Daly asked the Minister for Health her views on whether the ongoing delay in concluding reimbursement negotiations for skyclarys for patients with Friedreich’s ataxia is consistent with the commitment to “equitable access” set out in the recently launched National Rare Disease Strategy 2025–2030; and if she will make a statement on the matter. [30202/26]
1274. Deputy Roderic O'Gorman asked the Minister for Health the reason imvaggis is not covered by the free HRT scheme; if consideration can be given to its inclusion in the scheme; and if she will make a statement on the matter. [30897/26]
1276. Deputy Pádraig O'Sullivan asked the Minister for Health whether her Department has identified which of the medicines currently in shortage across the European Union may pose a risk of shortage in Ireland; the measures in place to ensure continuity of supply and minimise patient impact; and if she will make a statement on the matter. [30904/26]
1278. Deputy Cormac Devlin asked the Minister for Health if she will provide an update on the NCPE appraisal of ritlecitinib (litfulo) for severe alopecia areata, including current stage, any ongoing HSE pricing and reimbursement engagement with the applicant, expected timelines for a decision, and proposed prescribing setting if approved (details supplied); and if she will make a statement on the matter. [30914/26]
1279. Deputy Cormac Devlin asked the Minister for Health if an application has been received by the HSE for pricing and reimbursement of baricitinib for the alopecia areata indication; if not, whether the HSE or her Department has engaged with the marketing authorisation holder regarding a submission (details supplied); and if she will make a statement on the matter. [30915/26]
1280. Deputy Cormac Devlin asked the Minister for Health whether her Department, the HSE or the HPRA has engaged with the manufacturer of deuruxolitinib (leqselvi) regarding plans for EU submission and availability in Ireland; whether any named-patient or compassionate access requests have been received (details supplied); and if she will make a statement on the matter. [30916/26]
1281. Deputy Cormac Devlin asked the Minister for Health if she will outline whether JAK inhibitor treatments for severe alopecia areata, where reimbursed, will be provided via the High Tech Arrangement; the intended initiation and monitoring setting; the proposed stop rules; the estimated annual budget impact and eligible patient numbers (details supplied); and if she will make a statement on the matter. [30917/26]
1282. Deputy Cormac Devlin asked the Minister for Health the number of patients treated for alopecia areata with JAK inhibitors in public hospitals in each of the past three years, by CHO and by medicine, including any named-patient access, and associated monitoring protocols; and if she will make a statement on the matter. [30918/26]
554. Deputy Gillian Toole asked the Minister for Health the reason drug companies are indemnified if vaccines are presented to the public as being safe and effective. [29477/26]
558. Deputy Gillian Toole asked the Minister for Health the reason drug companies indemnified are if vaccines are presented to the public as being safe and effective. [29492/26]